Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer - Concepedia

Concepedia

Publication | Open Access

Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer

DOI Full Paper Access

15

Citations

35

References

2022

Year

Jonathan Alexander Chatzkel, Michael J. Schell, Jad Chahoud, Jingsong Zhang, Rohit K. Jain, Jennifer Swank, Steve Ludlow, Kristina Lombardi, Yesenia Lucas, Cortlin Croft,

Clinical Genitourinary Cancer

Abstract

The combination of 5-planned-dose-schedule high dose IL-2 and pembrolizumab is feasible, with a high response rate, justifying further exploration of this dual immune treatment of metastatic ccRCC.

References

	Year	Citations

Page 1